Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States
Author:
Affiliation:
1. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (R.A., N.C.).
2. Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (M.V., D.L.B.).
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cardiology and Cardiovascular Medicine
Link
https://www.ahajournals.org/doi/pdf/10.1161/CIRCHEARTFAILURE.121.009099
Reference5 articles.
1. Prevalence of individuals with diabetes and chronic kidney disease indicated for SGLT-2 inhibitor therapy;Aggarwal R;J Am Coll Cardiol.,2020
2. Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST-WHF in perspective;Verma S;ESC Heart Fail.,2020
3. and out-of-pocket costs for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in the Medicare Part D Program;Luo J;JAMA Netw Open.,2020
4. The time is now for sodium glucose cotransporter 2 inhibitors for heart failure;Khan MS;Circ Heart Fail.,2020
5. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey (MEPS). https://www.ahrq.gov/cpi/about/otherwebsites/meps. ahrq.gov/index.html
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Disparities in Use of Novel Diabetes Medications by Insurance: A Nationally Representative Cohort Study;Journal of General Internal Medicine;2024-07-31
2. Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor for the treatment of type 2 diabetes mellitus;Medicinal Chemistry Research;2024-07-10
3. Out-of-pocket prescription drug costs for adults with cardiovascular risk factors under Amazon's direct-to-consumer pharmacy service;American Heart Journal;2024-05
4. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes;Journal of Medical Economics;2024-03-11
5. Paving a Path to Equity in Cardiorenal Care;Seminars in Nephrology;2024-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3